Brief: Erytech Announces Results Of Expanded Access Program In ALL

Phaxiam Therapeutics SA

14/12/2021 07:28

Dec 14 (Reuters) - ERYTECH PHARMA SA  ERYP.PA :
    * ANNOUNCED ON MONDAY PRESENTATION OF FULL RESULTS OF THE
EXPANDED
ACCESS PROGRAM IN 'DOUBLE ALLERGIC' ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL) PATIENTS
    * RESULTS HIGHLIGHTING THE FEASIBILITY OF ERYASPASE
(GRASPA®) TO
CONTINUE THE INTENDED COURSE OF TREATMENT OF ALL PATIENTS WHO
DEVELOPED HYPERSENSITIVITIES TO OTHER ASPARAGINASES
    * FULL RESULTS FROM PHASE 3 TRYBECA-1 STUDY OF ERYASPASE IN
SECOND-LINE METASTATIC PANCREATIC CANCER ACCEPTED FOR ORAL
PRESENTATION ON JANUARY 21
    * INTERIM DATA FROM THE PHASE 1 RESPECT TRIAL OF ERYASPASE
PLUS
MFOLFIRINOX IN FIRST-LINE PANCREATIC CANCER PATIENTS WILL BE
PROVIDED ON JANUARY 21
    * THIS STUDY IS THE FIRST STUDY TO DEMONSTRATE ACTIVITY OF
AN
ASPARAGINASE (ASNASE) THERAPY IN A DOUBLE (AND EVEN TRIPLE)
ALLERGIC PATIENT POPULATION WHO RECEIVED PRIOR E. COLI- AND
ERWINIA-DERIVED ASPARAGINASE
    * ALL EXCEPT ONE OF THE 18 PATIENTS IN THE STUDY ACHIEVED
COMPLETE
REMISSION AND 14 (77.8%) WERE STILL ALIVE AT THE END OF THE
STUDY
    * ERYASPASE WAS WELL-TOLERATED WHEN COMBINED WITH
CHEMOTHERAPY FOR
TREATMENT OF PATIENTS WITH ALL
    * ERYASPASE PROVIDES AN ADDITIONAL OPTION FOR PATIENTS FOR
WHOM
FURTHER ASNASE TREATMENT IS CONTRAINDICATED DUE TO TOXICITY
    * COMPANY IS CURRENTLY PREPARING A BLA TO SEEK APPROVAL FOR
ALL
PATIENTS WHO DEVELOPED HYPERSENSITIVITY TO E. COLI-DERIVED
ASPARAGINASE, BASED ON THE RESULTS OF A PHASE 2 CLINICAL TRIAL
SPONSORED BY THE NOPHO GROUP
    * COMPANY INTENDS TO SUBMIT THE BLA IN THE FIRST QUARTER OF
2022,
SUBJECT TO COMPLETION OF REMAINING DATA REQUESTED BY THE FDA

    

Source text for Eikon:  ID:nGNX7Cgv5T 
Further company coverage:  ERYP.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))